Switch to Fixed-Dose Doravirine/Islatravir (100/0.75 mg) Once Daily in Adults with HIV-1 Virologically Suppressed on Biktarvy - week 96 results of a phase 3, randomized, double-blind, non-inferiority trial

Conference Reports for NATAP

19th European AIDS Conference
October 18th-21st , 2023
Warsaw, Poland


Switch to Fixed-Dose Doravirine/Islatravir (100/0.75 mg) Once Daily in Adults with HIV-1 Virologically Suppressed on Biktarvy - week 96 results of a phase 3, randomized, double-blind, non-inferiority trial

	EACS 2023 Oct 20